Piper Sandler Raises Price Target on SharkNinja
Piper Sandler maintained a Buy rating on SharkNinja (SN) and increased its price target from $200 to $234.
Stocks · News reference
Piper Sandler Acts as Joint Bookrunning Manager for Aclaris Therapeutics Offering
Piper Sandler is serving as a joint bookrunning manager for Aclaris Therapeutics' offering of common stock and pre-funded warrants.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Piper Sandler Serves as Financial Advisor to Delta Group in A&M Capital Acquisition
Piper Sandler acted as the exclusive financial advisor to Delta Group, a provider of investigative and claims support services, in connection with its acquisition by A&M Capital.
Piper Sandler Downgrades F5 to Neutral From Overweight
Piper Sandler has downgraded F5, Inc. from Overweight to Neutral, setting a price target of $461.
Piper Sandler Maintains Buy Rating on Baker Hughes
Piper Sandler analyst Derek Podhaizer has maintained a Buy rating and a $73 price target on Baker Hughes.